Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1...
CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, announced that its CE...
– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 ...
QIAGEN N.V. announced a notice (reiterating its notice to holders dated January 9, 2019) to holders of the following: - 0.500% Senior Unsecure...
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease an...
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comp...
Agilent Technologies Inc. (NYSE: A) announced the results of an independent third-party global survey that will help the industry better unders...
“The acquisition of VGYAAN Pharmaceuticals aligns strongly with our growth strategy that will deliver substantial value for our company, customers, a...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new systematic evaluation that underlines the unique benefits of the compa...
Under the terms of the agreement, the two companies aim to develop multiple targeted protein degraders by combining Cullgen's proprietary uSMITE™ tar...
Report now includes Scope 3 emissions Employee-driven social responsibility takes precedence as driving force for sustainability activities Goal to red...
Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetyl...
Gavi, the Vaccine Alliance, and the Eleanor Crook Foundation (ECF) announced at the Global Vaccine Impact Conference a US$2 million joint investment in the...
The repurchases will be executed through one or more individual forward transactions, expected to be entered into in the second and/or the third quarter of...
© 2025 Biopharma Boardroom. All Rights Reserved.
